Phathom Pharmaceuticals is shifting focus to gastroenterology, expecting $55 million in 2024 revenue and $175 million in 2025 from their drug VOQUEZNA. The company aims to reach operating profitability by the second half of 2026 and convert 20-30% of GI PPI scripts to drive $1 billion in revenue. Regulatory exclusivity for VOQUEZNA runs through May 2032.

CEO Steven Basta revealed Phathom’s commercial focus on gastroenterology, emphasizing VOQUEZNA as the first P-CAB in the U.S. for GERD. The drug targets patients still symptomatic on existing therapies, with $55 million in 2024 revenue and an estimated $175 million in 2025. Operating profitability is expected in the second half of 2026.

Phathom made strategic changes to pivot sales efforts towards gastroenterologists, aiming to convert 20-30% of GI PPI scripts to VOQUEZNA for $1 billion in revenue from GI scripts alone. The company plans to reach a full-strength sales organization of around 300 representatives by March 2026, focusing on gastroenterology.

The company raised capital to address debt overhang and achieve operating profitability by the second half of 2026. Phathom’s exclusivity for VOQUEZNA runs through May 2032, with potential extensions. The company is evaluating longer-term business opportunities leveraging its gastroenterology-focused infrastructure.

Read more at Yahoo Finance: Phathom Pharmaceuticals Pivots to GI Focus, Targets 2H 2026 Profitability, CEO Says at Guggenheim Summit